FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2328430079> ?p ?o ?g. }

• W2328430079 endingPage "14003" @default.
• W2328430079 startingPage "14003" @default.
• W2328430079 abstract "Carbonic anhydrase IX (CAIX) is a tumor-associated antigen and marker of hypoxia that is overexpressed on > 90% of clear-cell type renal cell carcinoma (RCC) but not on neighboring normal kidney tissue. Here, we report on the construction of two chimeric antigen receptors (CARs) that utilize a carbonic anhydrase (CA) domain mapped, human single chain antibody (scFv G36) as a targeting moiety but differ in their capacity to provide costimulatory signaling for optimal T cell proliferation and tumor cell killing. The resulting anti-CAIX CARs were expressed on human primary T cells via lentivirus transduction. CAR-transduced T cells (CART cells) expressing second-generation G36-CD28-TCRζ exhibited more potent in vitro antitumor effects on CAIX+ RCC cells than first-generation G36-CD8-TCRζ including cytotoxicity, cytokine secretion, proliferation, and clonal expansion. Adoptive G36-CD28-TCRζ CART cell therapy combined with high-dose interleukin (IL)-2 injection also lead to superior regression of established RCC in nude mice with evidence of tumor cell apoptosis and tissue necrosis. These results suggest that the fully human G36-CD28-TCRζ CARs should provide substantial improvements over first-generation mouse anti-CAIX CARs in clinical use through reduced human anti-mouse antibody responses against the targeting scFv and administration of lower doses of T cells during CART cell therapy of CAIX+ RCC. Carbonic anhydrase IX (CAIX) is a tumor-associated antigen and marker of hypoxia that is overexpressed on > 90% of clear-cell type renal cell carcinoma (RCC) but not on neighboring normal kidney tissue. Here, we report on the construction of two chimeric antigen receptors (CARs) that utilize a carbonic anhydrase (CA) domain mapped, human single chain antibody (scFv G36) as a targeting moiety but differ in their capacity to provide costimulatory signaling for optimal T cell proliferation and tumor cell killing. The resulting anti-CAIX CARs were expressed on human primary T cells via lentivirus transduction. CAR-transduced T cells (CART cells) expressing second-generation G36-CD28-TCRζ exhibited more potent in vitro antitumor effects on CAIX+ RCC cells than first-generation G36-CD8-TCRζ including cytotoxicity, cytokine secretion, proliferation, and clonal expansion. Adoptive G36-CD28-TCRζ CART cell therapy combined with high-dose interleukin (IL)-2 injection also lead to superior regression of established RCC in nude mice with evidence of tumor cell apoptosis and tissue necrosis. These results suggest that the fully human G36-CD28-TCRζ CARs should provide substantial improvements over first-generation mouse anti-CAIX CARs in clinical use through reduced human anti-mouse antibody responses against the targeting scFv and administration of lower doses of T cells during CART cell therapy of CAIX+ RCC." @default.
• W2328430079 created "2016-06-24" @default.
• W2328430079 creator A5000780125 @default.
• W2328430079 creator A5042281153 @default.
• W2328430079 creator A5046619240 @default.
• W2328430079 creator A5055008068 @default.
• W2328430079 date "2014-01-01" @default.
• W2328430079 modified "2023-10-15" @default.
• W2328430079 title "Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor" @default.
• W2328430079 cites W1561382837 @default.
• W2328430079 cites W1623064933 @default.
• W2328430079 cites W1857289711 @default.
• W2328430079 cites W1964034932 @default.
• W2328430079 cites W1964312509 @default.
• W2328430079 cites W1967517831 @default.
• W2328430079 cites W1970636382 @default.
• W2328430079 cites W1986193304 @default.
• W2328430079 cites W1987504267 @default.
• W2328430079 cites W1995351026 @default.
• W2328430079 cites W1996400431 @default.
• W2328430079 cites W1999971211 @default.
• W2328430079 cites W2002958741 @default.
• W2328430079 cites W2005623930 @default.
• W2328430079 cites W2007753570 @default.
• W2328430079 cites W2013971016 @default.
• W2328430079 cites W2019602861 @default.
• W2328430079 cites W2025196759 @default.
• W2328430079 cites W2026411584 @default.
• W2328430079 cites W2039722097 @default.
• W2328430079 cites W2042177508 @default.
• W2328430079 cites W2051920977 @default.
• W2328430079 cites W2056662191 @default.
• W2328430079 cites W2064272625 @default.
• W2328430079 cites W2073821210 @default.
• W2328430079 cites W2091334680 @default.
• W2328430079 cites W2092475062 @default.
• W2328430079 cites W2093654081 @default.
• W2328430079 cites W2093853778 @default.
• W2328430079 cites W2098203439 @default.
• W2328430079 cites W2107765339 @default.
• W2328430079 cites W2107806760 @default.
• W2328430079 cites W2109086596 @default.
• W2328430079 cites W2111876649 @default.
• W2328430079 cites W2113802879 @default.
• W2328430079 cites W2113989224 @default.
• W2328430079 cites W2114601875 @default.
• W2328430079 cites W2115342244 @default.
• W2328430079 cites W2115475680 @default.
• W2328430079 cites W2135687519 @default.
• W2328430079 cites W2141553969 @default.
• W2328430079 cites W2145758395 @default.
• W2328430079 cites W2149861830 @default.
• W2328430079 cites W2151246207 @default.
• W2328430079 cites W2164791849 @default.
• W2328430079 cites W2166609587 @default.
• W2328430079 cites W2167550136 @default.
• W2328430079 cites W2329610838 @default.
• W2328430079 cites W4247687303 @default.
• W2328430079 cites W7051800 @default.
• W2328430079 doi "https://doi.org/10.1038/mto.2014.3" @default.
• W2328430079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4782938" @default.
• W2328430079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27119093" @default.
• W2328430079 hasPublicationYear "2014" @default.
• W2328430079 type Work @default.
• W2328430079 sameAs 2328430079 @default.
• W2328430079 citedByCount "15" @default.
• W2328430079 countsByYear W23284300792015 @default.
• W2328430079 countsByYear W23284300792016 @default.
• W2328430079 countsByYear W23284300792017 @default.
• W2328430079 countsByYear W23284300792018 @default.
• W2328430079 countsByYear W23284300792019 @default.
• W2328430079 countsByYear W23284300792020 @default.
• W2328430079 countsByYear W23284300792021 @default.
• W2328430079 countsByYear W23284300792022 @default.
• W2328430079 crossrefType "journal-article" @default.
• W2328430079 hasAuthorship W2328430079A5000780125 @default.
• W2328430079 hasAuthorship W2328430079A5042281153 @default.
• W2328430079 hasAuthorship W2328430079A5046619240 @default.
• W2328430079 hasAuthorship W2328430079A5055008068 @default.
• W2328430079 hasBestOaLocation W23284300791 @default.
• W2328430079 hasConcept C147483822 @default.
• W2328430079 hasConcept C148125776 @default.
• W2328430079 hasConcept C153911025 @default.
• W2328430079 hasConcept C154317977 @default.
• W2328430079 hasConcept C167672396 @default.
• W2328430079 hasConcept C19317047 @default.
• W2328430079 hasConcept C202751555 @default.
• W2328430079 hasConcept C203014093 @default.
• W2328430079 hasConcept C2776090121 @default.
• W2328430079 hasConcept C2776662205 @default.
• W2328430079 hasConcept C2777701055 @default.
• W2328430079 hasConcept C3875195 @default.
• W2328430079 hasConcept C502942594 @default.
• W2328430079 hasConcept C55493867 @default.
• W2328430079 hasConcept C86803240 @default.
• W2328430079 hasConcept C8891405 @default.
• W2328430079 hasConcept C90375314 @default.
• W2328430079 hasConceptScore W2328430079C147483822 @default.

• next